Due to the lack of significant differences in CD56+ and CD16+CD56+ cells between severe and moderate patients as well as deceased and discharged patients, it seems that the increase in FcγRIII can be due to the increase in peripheral blood monocytes in patients with COVID-19. This evidence concerns the gene NCAM1 and COVID-19.